By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


CN Bio Innovations (Formerly known as Zyomyx, Inc.) 

6519 Dumbarton Circle

Fremont  California  94555  U.S.A.
Phone: 510-265-8000 Fax: 510-784-2569


Zyomyx, Inc. is a privately held diagnostics company based in Fremont, California -- a developer, manufacturer and marketer of innovative point-of-care diagnostic products.

Do you want to make a positive contribution to humanity -- one that significantly impacts the international community, a cause which engages heads of nations? Do you want to join an entrepreneurial and growing diagnostics company that functions with the electricity of a startup, but one that has stood the test of time? At Zyomyx, you get the best of both worlds!

We are on a powerful and important mission -- charting the course for not only improving quality of life, but contributing to saving millions of lives in countries around the world. Zyomyx has also attracted the attention of and entered into an exclusive distribution agreement with Mylan, global pharmaceutical giant with 10+ years’ presence in emerging markets, to distribute its revolutionary MyT4 POC CD4 diagnostic test for HIV/AIDs in the developing world. Mylan chose Zyomyx as its first entry into the diagnostics market to set new standards in health care, realizing that the MyT4 test provides “gold standard” accuracy, enables access for patients and cost effectiveness for national HIV programs, contributing a critical tool to reach the goal of universal access to treatment for the 28 million people living with HIV globally. Other benefits of this diagnostic test are ease of use, portability, and service-free configuration.

While Zyomyx focuses INITIALLY on this key core product, we also know that incredible future potential opportunities exist from our other various core technology platforms to bring complex lab diagnostics into POC, a growing and burgeoning worldwide market. As a result, the Company will launch follow-on products for launch in markets of high income countries over the coming years

Our culture represents innovative, driven and talented individuals bringing diverse perspectives, and one which is united on a mission to significantly and positively impact lives globally.

Key Statistics

Ownership: Private

Web Site: CN Bio Innovations
Employees: 70

Medical Device

Company News
CN Bio Innovations Marks World Hepatitis Day By Signing Research Agreement With Imperial College London 7/28/2014 8:13:07 AM
3D Liver Model Expert Zyoxel Ltd To Become CN Bio Innovations 2/10/2014 9:42:25 AM
Mylan Inc. (MYL) and Zyomyx, Inc. Enter into Exclusive Distribution Agreement for Innovative Point-of-Care CD4 Diagnostic Test, Enhancing Mylan's Leadership Position in HIV Care 7/1/2013 10:14:48 AM
Zyomyx, Inc. Lands $12 Million to Enable Launch of Low-Cost, Rapid Point-of-Care CD4 Test 7/1/2013 6:42:37 AM
Zyomyx, Inc. Receives ISO 13485: 2003 Certification 2/28/2013 10:27:34 AM
Zyomyx, Inc. Announces Appointment of Chief Financial Officer 9/24/2012 9:29:12 AM
Zyomyx, Inc. Awarded Grant from the CD4 Initiative at Imperial College London 3/8/2007 10:20:41 AM
Invitrogen Corporation (IVGN) Licenses Key Protein Chip Intellectual Property From Zyomyx, Inc.; Broad Manufacturing Patents Strengthen Invitrogen's Position In Protein Microarrays10/19/2005 5:12:20 PM
Zyomyx, Inc. Names Peter Wagner CEO And Unveils New Business Strategy10/19/2005 5:12:13 PM
$100 Million In State-of-the-Art Biotechnology And Semiconductor Equipment Hits The Auction Block10/19/2005 5:12:02 PM